Prevalence and Associated Factors for Receiving Psychotropic Medications in Dementia Patients with Neuropsychiatric Symptoms
Article Sidebar
Main Article Content
Abstract
Background: Neuropsychiatric symptoms (NPS) are common manifestations in dementia patients. The first line treatment for NPS is non-pharmacological methods. However, psychotropic drugs (PD) are necessity in some patients for controlling these symptoms. Objective: To determine the prevalence of dementia patients with NPS who used PD and to identify the associated factors for receiving this medications at Memory clinic, Maharat Nakhon Ratchasima Hospital (MNRH). Patients and Methods: A cross-sectional study in dementia patients who had NPS was performed at Memory clinic, MNRH between January and June 2013.The NPS were documented by using Neuropsychiatric Inventory (NPI) questionnaire. The baseline characters and type of PD (antipsychotics, mood stabilizers, antidepressants and hypnotics) that patient used were collected. All data were analyzed to identify the prevalence and the associated factors for using of PD in dementia patients who had NPS. Results: There were 65 dementia patients with NPS with mean age of 73.9+8.1 years in the study. Alzheimer’s disease was the most common type of dementia (47.7%). Fifty-three point eight percent of patients received PD. Antipsychotic was the commonly used medication (30.8%), followed by hypnotic drugs (16.9%). The advancing age, the more numbers of NPS and low cognitive status were the associated factors for receiving PD. Conclusion: The prevalence of dementia patients with NPS who received PD at Memory clinic, MNRH was 53.8%. Advancing age, low cognitive performance and the more numbers of NPS were the associated factors for receiving these medications.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Jitapunkul S, Kunanusont C, Phoolcharoen W, Suriyawongpaisal P. Prevalence estimation of dementia among Thai elderly: a national survey. J Med Assoc Thai 2001; 84: 461-7.
Rubin EH, Kinscherf DA. Psychopathology of very mild dementia of the Alzheimer type. Am J Psychiatry 1989; 146: 1017-21.
Stern Y, Tang MX, Albert MS, Brandt J, Jacobs DM, Bell K, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997; 277: 806-12.
Mekawichai P. Prevalence of neuropsychiatric symptoms in dementia and their associated factors: A cross-sectional study. I-san J of Intern Med 2013; 4: 23-31.
Gonzแlez-Salvador T, Lyketsos CG, Baker A, Hovanec L, Roques C, Brandt J, et al. Quality of life in dementia patients in long-term care. Int J Geriatr Psychiatry 2000; 15: 181-9.
Psychiatry Association. Diagnostic and statistical manual of mental disorders text revised. (DSM-IV-TR) 4th edition. Washington (DC): American psychiatric Press; 2000.
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
Train the Brain Forum Committee. Thai Mental State Examination (TMSE). Siriraj Hosp Gaz 1993; 45: 359-74.
Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebocontrolled trials. JAMA 2005; 294: 1934-43.
Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 2012; 169: 71-9.
Piersanti M, Capannolo M, Turchetti M, Serroni N, De Berardis D, Evangelista P, et al. Increase in mortality rate in patients with dementia treated with atypical anti-psychotics: a cohort study in outpatients in Central Italy. Riv Psichiatr. 2014; 49: 34-40.
Nijk RM, Zuidema SU, Koopmans RT. Prevalence and correlates of psychotropic drug use in Dutch nursing-home patients with dementia. Int Psychogeriatr 2009; 21: 485-93.
Kim H, Whall AL. Factors associated with psychotropic drug usage among nursing home residents with dementia. Nurs Res 2006; 55: 252-8.
Petek SM, Cedilnik GE. Psychotropic medication use among elderly nursing home residents in Slovenia: cross-sectional study. Croat Med J 2011; 52: 16-24.
Barnes TR, Banerjee S, Collins N, Treloar A, McIntyre SM, Paton C, et al. Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services. Br J Psychiatry 2012; 201: 221-6.
Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC. Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 2011; 68: 899-904.
Frenchman IB. Atypical antipsychotics for nursing home patients: a retrospective chart review. Drug Aging 2005; 22: 257-64.
Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s dis ease: phase 1 outcomes from the CATIE-AD effectiv ness trial. AM J Psychiatry 2008; 165: 844-54.
Monette J, Alessa W, McCusker J, Cole M, Voyer P, Champoux N, et al. Association of resident and room characteristics with antipsychotic use in long-term care facilities (LTCF). Arch Gerontol Geriatr 2012; 55: 66-9.
Kleijer BC, van Marum RJ, Frijters DH, Jansen PA, Ribbe MW, Egberts AC, et al. Variability between nursing homes in prevalence of antipsychotic use in patients with dementia. Int Psychogeriatr 2014; 26: 363-71.
Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT. Psychotropic drug prescription in nursing home patients with dementia: influence of environmental correlates and staff distress on physicians’ prescription behavior. Int Psychogeriatr 2011; 23: 1632-9.